Missouri American Water Proudly Recognizes American Water Charitable Foundation Hydration Station Grantees
ST. LOUIS--(BUSINESS WIRE)--The American Water Charitable Foundation, a philanthropic non-profit organization established by American Water (NYSE: AWK), the largest regulated water and wastewater utility company in the U.S., and Missouri American Water, announced today that the Foundation awarded $21,025 in Hydration Station grants to 11 organizations to help purchase bottle fillers and/or drinking fountains for sustainable and safe hydration in Missouri communities.
'Accessible drinking water is a resource many take for granted,' said Rich Svindland, president of Missouri American Water.
'Accessible drinking water is a resource many take for granted,' said Rich Svindland, president of Missouri American Water. 'We are proud to offer an opportunity for community organizations to provide sustainable, accessible and healthy hydration for visitors and staff.'
Each day in the United States more than 60 million plastic water bottles end up in landfills and incinerators, according to the Container Recycling Institute. Hydration stations help reduce the number of single-use plastic bottles that end up in landfills and sources of drinking water.
Funding for the hydration station grants will be provided by the American Water Charitable Foundation, as part of its State Strategic Grant Program, focused on high-impact projects and initiatives throughout American Water's national footprint.
'We're so thankful to Missouri American Water for helping us add a hydration station to the House. It's another way we can provide care and support. Staying hydrated is important—especially for breastfeeding moms. This upgrade makes it easier for families to take care of themselves while staying strong for their little ones,' said Lori Jones, executive director of Ronald McDonald House Charities of the Four States.
The 2025 hydration station grantees:
Twillman Elementary School
Pershing Elementary School
United Way of Greater St. Joseph
Jennings School District
Valley Park School District
Jefferson City School District
Rockwood School District
Joplin Softball Little League Inc.
Bayless Elementary School
Lawson R-XIV School District
Ronald McDonald House Charities of the Four States
'The American Water Charitable Foundation is pleased to partner with organizations that align with Missouri American Water and support the addition of sustainable hydration stations for community members,' said Carrie Williams, President, American Water Charitable Foundation.
Learn more about the American Water Charitable Foundation here.
About American Water
American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to more than 14 million people with regulated operations in 14 states and on 18 military installations. American Water's 6,700 talented professionals leverage their significant expertise and the company's national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders.
For more information, visit amwater.com and join American Water on LinkedIn, Facebook, X and Instagram.
About American Water Charitable Foundation
The American Water Charitable Foundation, a philanthropic non-profit organization established by American Water (NYSE: AWK), focuses on three pillars of giving: Water, People, and Communities. Since 2012, the Foundation has invested more than $20 million in funding through grants and matching gifts to support eligible organizations in communities served by American Water. The Foundation is funded by American Water shareholders and has no impact on customer rates. For more information, visit amwater.com/awcf.
About Missouri American Water
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
6 hours ago
- Business Insider
Molina Healthcare (MOH) Receives a Buy from Bernstein
In a report released today, Lance Wilkes from Bernstein maintained a Buy rating on Molina Healthcare (MOH – Research Report), with a price target of $414.00. The company's shares closed today at $296.88. Confident Investing Starts Here: According to TipRanks, Wilkes is a 2-star analyst with an average return of -0.3% and a 42.86% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Humana, and Elevance Health. In addition to Bernstein, Molina Healthcare also received a Buy from Wells Fargo's Stephen Baxter in a report issued yesterday. However, on June 3, Barclays maintained a Hold rating on Molina Healthcare (NYSE: MOH). Based on Molina Healthcare's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $11.15 billion and a net profit of $298 million. In comparison, last year the company earned a revenue of $9.93 billion and had a net profit of $301 million Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MOH in relation to earlier this year. Last month, Dale Wolf, a Director at MOH sold 1,500.00 shares for a total of $484,328.00.
Yahoo
12 hours ago
- Yahoo
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th Annual Global Healthcare Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, June 10th at 2:00 p.m. Eastern Time. Citizens Medical Devices and Healthcare Services Forum: Ben Berry, Chief Financial Officer, will participate in investor meetings on Tuesday, June 17th. A link to the live audio webcasts, if available, as well as a replay of these events, will be available on the Company's website under the Investors tab at Events and Presentations. ABOUT ENOVIS Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company's extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company's shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit Contact: Kyle RoseVice President, Investor RelationsEnovis Corporationinvestorrelations@
Yahoo
14 hours ago
- Yahoo
Should You Invest $1,000 in Eli Lilly today?
Eli Lilly is a pharma player, but it offers the growth of a tech stock thanks to its weight loss drugs portfolio. The weight loss market could represent a multibillion-dollar opportunity well into the next decade. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. The pharma giant's presence across several treatment areas has helped it grow earnings over time. But, in recent years, one particular product portfolio has stood out and driven double-digit revenue growth: drugs to help people lose weight. Right now, Lilly sells tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight loss, though doctors have prescribed either one for patients hoping to shed pounds. Mounjaro and Zepbound each have become blockbusters, bringing in billion-dollar revenue annually. Lilly dominates the weight loss market along with rival Novo Nordisk, but a recent move by Lilly could help it push farther ahead in the coming years. Considering this, should you invest $1,000 in Lilly stock today? Let's find out. So, first, let's talk about Lilly's path so far in this market and what might lie ahead. Lilly's weight loss drugs are part of a class known as dual GIP and GLP-1 receptor agonists. They act on hormonal pathways involved in the digestion process and help control blood sugar levels and appetite. Novo Nordisk's rival drug, semaglutide -- sold as Ozempic for type 2 diabetes and Wegovy for weight loss -- targets only GLP-1 but works in a similar way. Novo Nordisk was first to market with its product, winning approval for Ozempic in 2017, and this offered it time to build a market-leading position. But demand has been so high for such weight loss drugs that Lilly quickly gained share soon after entering the market with Mounjaro in 2022 and then with Zepbound in 2023. In fact, demand has been so strong that these drugs held spots on the U.S. Food and Drug Administration's drug shortage list for quite some time, only exiting the list in recent months. A better supply situation for weight loss drugs isn't due to a drop in demand but instead to increases in manufacturing capacity by both companies. So solid demand for these products still exists -- and is likely to grow. It's important to keep in mind, though, that both Lilly and rivals may face some headwinds in the years to come, and that's why Goldman Sachs Research recently reduced its forecast for global sales of anti-obesity medicines to $95 billion by 2030, from an earlier forecast of $130 billion. This is due to several potential challenges, including lower per-unit prices and weaker reimbursement from certain insurers. But even considering the challenges, "we see a significant growth opportunity for both existing players as well as new entrants into this market," said Goldman analyst Asad Haider. After all, from today's $28 billion market, the forecast figure represents a 239% increase. A look at Lilly's weight loss drug sales shows us this company has the momentum to benefit from this high-growth market. Last year, Mounjaro and Zepbound generated more than $11 billion and $4.9 billion in sales, respectively. And these two products are driving double-digit total sales growth at Lilly -- with a 32% gain in the full year and a 45% gain in the most recent quarter. Now, what may push Lilly past Novo Nordisk -- and keep it far ahead of newer rivals down the road -- is the company's progress on an oral weight loss candidate. Current products are in injectable form, which may be less convenient and even uncomfortable for certain users. Lilly recently reported positive results from a phase 3 trial of its oral candidate, orforglipron, and plans to request approval for use in weight management by the end of the year. Though Novo Nordisk sells an oral form of semaglutide, it involves strict food and water guidelines. The potential Lilly product doesn't, offering it a significant advantage. Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward earnings estimates -- that's around the same level as top tech companies such as Amazon and Nvidia, also known for delivering double-digit revenue growth. In fact, since the launch of tirzepatide, Lilly has traded at valuations resembling those of growth stocks. So it may seem pricey to you for a pharmaceutical player. But it's worth keeping in mind that Lilly stands out from the pharma crowd due to its presence in the high-growth market of weight loss drugs, yet at the same time it offers you the stability and dividend growth of a pharma stock. You generally can count on big pharma companies for steady revenue since patients always need their medicines -- regardless of the economic situation. And you can count on Lilly for passive income too, with a forward dividend of $6, representing a dividend yield of 0.8%. Meanwhile, valuation has come down from its peak to levels that look very acceptable for a growth stock. All of this means that, by investing in Lilly, you're getting growth worthy of a tech company along with the safety generally associated with a pharma stock. That makes the stock well worth the price, and a great place to park $1,000 right now. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Goldman Sachs Group, and Nvidia. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Should You Invest $1,000 in Eli Lilly today? was originally published by The Motley Fool Sign in to access your portfolio
